Article
<i>In silico</i> discovery of pathogenic PD-L1 nsSNVs with aberrant glycosylation and immunotherapy binding
2025-06-19
Abstract excerpt
Immune checkpoint inhibitors (ICIs), particularly anti-PD-L1 monoclonal antibodies, block extracellular interactions between programmed death ligand-1 (PD-L1) and programmed cell death protein-1 (PD-1) to enhance antitumour immunity. Here, we present a streamlined workflow integrating public databases, bioinformatics tools, and in silico molecular dynamics (MD) simulations and in vitro experimental assays to ide...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- b3d10c98-c542-5b1d-af15-c3cc287be339
- DOI
- 10.1101/2025.06.17.660108
